IMFINZI® (Durvalumab)

The FDA on March 28, 2025, approved IMFINZI® with Gemcitabine and Cisplatin as neoadjuvant treatment, followed by single agent IMFINZI® as adjuvant treatment following radical cystectomy, for adults with Muscle Invasive Bladder Cancer (MIBC). IMFINZI® is a product of AstraZeneca.